Franklyn G. Prendergast, M.D., Ph.D., is a consultant in the Department of Molecular Pharmacology and Experimental Therapeutics and the Department of Biochemistry and Molecular Biology at Mayo Clinic in Rochester. He holds the academic rank of professor of biochemistry, molecular biology and pharmacology. In addition, he is recognized with the distinction of a named professorship, the Edmond and Marion Guggenheim Professorship of Biochemistry and Molecular Biology. He served as director of Mayo Clinic Cancer Center from 1994 to 2006 and currently is director of the Mayo Clinic Center for Individualized Medicine.
Dr. Prendergast obtained his medical degree with honors from the University of West Indies and attended Oxford University as a Rhodes Scholar, earning the M.A. degree in physiology. After an internal medicine residency at Mayo Clinic, Dr. Prendergast obtained the Ph.D. degree in biochemistry at the University of Minnesota/Mayo Graduate School.
Dr. Prendergast is the former chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic in Rochester from 1989-1992. From 1989-1996, inclusive, he was a member of the Board of Governors for Mayo Clinic in Rochester. He has served on Mayo Clinic Board of Trustees continuously between 1992-2009 also has served on Mayo Clinic’s Board of Governors, the senior governance committee responsible for governance of the entire institution. He was recognized as a Mayo Distinguished Investigator in 1988.
Extramurally, Dr. Prendergast has served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH and the National Research Council of the National Academy of Sciences, and he is a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).